Focus of research group (I)

Name PI: Michiel Coppens
Department, UMC: Vascular Medicine/Hemophilia Treatment Centre
Size of research group:
PhD candidates: Bavalia, Hamulyak (thrombosis), Zwagemaker, Kloosterman, Abdi (bleeding)

Current mission, vision and aims

1. Clinical research that can directly impact patient care.
   a) Management and outcome of anticoagulant associated bleeding
   b) Management of menorrhagia in women treated with oral anticoagulants.
   c) Oral resorption of DOACs in patients with short bowel syndrome
   d) Gene therapy for haemophilia A/B
   e) Bleeding phenotype in non-severe haemophilia
Focus of research group (II)

Current expertise
1. Reversal of DOACs / Bleeding registr(ies)
2. Mennorhagia (collaboration Middeldorp)
3. Oral DOAC resorption in Short Bowel Syndrome (collaboration Mathot/Serlie)
   • Successful pilot, prospective cohort ongoing
4. Gene therapy
   • Steering committee AMT-060/Uniqure Phase I/II
5. Phenotype in non-severe haem A/B (collaboration Fijnvandraat)
   • Dynamo, Flow cohorts
6. National haemophilia collaborations
   • HiN-6, TiN, Opticlot, DAVID, Pride

Current funding
• ZonMW GGG (in afronding)
• CSL Behring Heimburger Grant
• Bayer Haemophilia Awards Program
• Vierde geldstroom
Future plans

Short term (1-2 year) plan
Plan:
• Wrap-up ZonMW GGG Grant. Explore international continuation of cohort
• Successful rollout of prospective TPN cohort (expansion to Radboud)
  • Expand to bariatric surgery patients?
• Gene therapy haemophilia
  • PI phase 3 AMT-061/UniQure
  • PI phase I Bayer
• Active participation in current national collaborations

Necessary infrastructure:
• HPLC DOACs (through Mathot)
• Affordable GCP-quality monitoring/support of IIS

Long term (>2 year) plan
Plan:
Try and remain active in two different fields...

Collaboration in ACS
Middeldorp